newsfilter
← Latest News
Business Wire·

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

– Study on track to begin later this year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat